Axsome Therapeutics, Inc. (AXSM) Aandelenanalyse

Bedrijfsoverzicht

Axsome Therapeutics, Inc. is a biopharmaceutical entity dedicated to the development and delivery of novel therapies designed for the management of central nervous system (CNS) disorders within the United States market. The company operates specifically within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized player focused on neurological treatments rather than broad-spectrum pharmaceuticals. In terms of operational scale, Axsome Therapeutics reports a market capitalization of $9.11 billion, generates annual revenue of $638.50 million, and employs a workforce of 925 individuals. These valuation and revenue figures indicate that the company has established a significant presence in the biotech landscape, with its commercial product portfolio anchored by Auvelity, which serves as a key driver for its substantial market cap despite the inherent risks associated with biotechnology development cycles.

Financiële gezondheid

The company reported revenue of $638.50 million over the trailing twelve months, yet this figure is offset by a net income loss of $-183.17 million and an EBITDA of $-160.17 million. The substantial gap between the positive revenue of $638.50 million and the negative net income reveals a cost structure where operating expenses and research and development costs significantly exceed current earnings before interest, taxes, and amortization. Free cash flow stands at $-29.42 million, indicating that the company is currently burning cash, which implies limited financial flexibility until future product launches or cost reductions generate positive cash generation. The company maintains a gross margin of 92.6%, reflecting the typical high-margin nature of biopharmaceutical sales, while the operating margin sits at -18.4% and the profit margin at -28.7%, highlighting the heavy burden of overhead and R&D expenses on bottom-line profitability. On the balance sheet, Axsome holds $322.93 million in cash against $218.11 million in debt, resulting in a debt-to-equity ratio of 247.03 which suggests a highly leveraged financial position relative to equity, though the cash buffer provides some immediate solvency. Liquidity is supported by a current ratio of 1.55, indicating that the company possesses sufficient short-term assets to cover its short-term liabilities without immediate distress. Return on Equity is reported at -252.1% and Return on Assets at -16.8%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and asset base, a common characteristic for pre-commercialization or early-commercialization biotech firms.

Waarderingsbeoordeling

Valuation metrics show a trailing P/E ratio of N/A due to the lack of positive net income, while the forward P/E is calculated at 29.23, implying that the market prices in anticipated future earnings recovery or profitability turning points. The price-to-book ratio stands at an elevated 102.66, indicating that the market assigns a significant premium to the company's book value, likely reflecting the high value placed on its intellectual property and potential pipeline assets. Alternative valuation measures include a price-to-sales ratio of 14.27 and an EV/EBITDA of -56.23, suggesting that investors are valuing the company primarily on its revenue generation potential rather than current earnings power or cash flow generation. The stock has traded between a 52-week low of $96.09 and a high of $191.50; without the specific current share price in the provided facts, the relative positioning within this $96.09 to $191.50 range cannot be precisely calculated, but the range demonstrates a substantial volatility envelope of over $95. The beta value is recorded at 0.47, which signifies that the stock's price volatility is less than the broader market, suggesting it moves with lower sensitivity to general market fluctuations compared to large-cap equities.

Growth & Income

Revenue growth accelerated to 65.0% year-over-year, whereas earnings growth is listed as N/A due to the company's current unprofitable status, implying that top-line expansion is outpacing bottom-line performance as the business scales. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all generated cash is retained within the company to fund operations and growth initiatives rather than being distributed to shareholders. The absence of a dividend payout is consistent with the company's life-cycle stage, where capital allocation prioritizes reinvestment into research, development, and commercialization efforts over income generation for investors. Overall, the growth and income profile is characterized by aggressive revenue expansion and zero current income distribution, reflecting a strategy focused on long-term value creation through product portfolio expansion rather than immediate shareholder returns.